The Complete Guide to Intracellular NAD+ Testing: NMN, NR, and Longevity Optimization

Why NAD+ Is the Master Regulator of Cellular Energy and Longevity

Nicotinamide adenine dinucleotide (NAD+) is not a supplement trend. It is a fundamental coenzyme present in every living cell, essential for converting food into ATP through the electron transport chain and serving as a critical signaling molecule that governs how cells respond to stress, damage, and aging. Understanding why NAD+ matters requires looking at four key biological systems it controls.

Sirtuin Activation

Sirtuins (SIRT1–SIRT7) are a family of NAD+-dependent deacetylases that regulate gene expression, inflammation, mitochondrial biogenesis, and DNA repair. They require NAD+ to function — without it, they are catalytically silent. SIRT1 and SIRT3 are particularly well-studied in longevity research; SIRT1 activates FOXO transcription factors and PGC-1α (the master regulator of mitochondrial biogenesis), while SIRT3 protects mitochondrial function under metabolic stress. When NAD+ declines, sirtuin activity collapses, accelerating the hallmarks of aging at the cellular level.

PARP DNA Repair

Poly(ADP-ribose) polymerases (PARPs), especially PARP1, are the genome's emergency responders. When DNA strand breaks occur — from UV radiation, oxidative stress, or replication errors — PARP1 immediately consumes large quantities of NAD+ to synthesize poly-ADP-ribose chains that signal the DNA repair machinery. During periods of high DNA damage load (aging, illness, radiation exposure), PARP1 activity can dramatically deplete cellular NAD+ pools, creating a vicious cycle: less NAD+ means less effective repair, which causes more DNA damage, which consumes more NAD+.

CD38 and the NAD+ Consumption Problem

CD38 is an NAD+ glycohydrolase — an enzyme that breaks down NAD+ — and it is arguably the most important driver of age-related NAD+ decline. CD38 expression increases dramatically with age and is further upregulated by inflammation (particularly via NF-κB signaling). Unlike sirtuins or PARPs, which consume NAD+ as part of productive enzymatic work, CD38 consumes NAD+ essentially as a byproduct of its role in calcium signaling and immune function. Studies in mice have shown that CD38 is responsible for consuming the majority of cellular NAD+, and that blocking CD38 pharmacologically or genetically can substantially restore NAD+ levels even in aged animals.

Mitochondrial Complex I

NAD+ is the electron acceptor at Complex I of the mitochondrial electron transport chain, where it accepts electrons from NADH to generate the proton gradient that drives ATP synthesis. This is not peripheral biochemistry — it is the core mechanism of aerobic energy production. When NAD+/NADH ratios fall (more NADH, less NAD+), Complex I activity slows, mitochondrial membrane potential drops, and cells shift toward less efficient glycolytic metabolism. This metabolic shift is observed in aging tissues and correlates with reduced physical capacity, impaired cognitive function, and accelerated metabolic disease.

How NAD+ Declines With Age — The Data

The age-related decline in NAD+ is not subtle. Multiple human studies using tissue biopsies, blood cell measurements, and skin samples have documented steep reductions across the lifespan. The most consistent finding: by age 50, most adults have approximately 50% of the intracellular NAD+ levels measured in young adults in their 20s. By age 70, some tissues show reductions exceeding 70%.

This decline is not uniform across tissues. Skeletal muscle and the brain are particularly vulnerable — both are high-energy-demand tissues that depend heavily on NAD+-dependent mitochondrial function. Liver and adipose tissue also show significant declines, with implications for metabolic health and insulin sensitivity.

What Drives the Decline?

Research has identified several converging mechanisms behind age-related NAD+ depletion:

• NAMPT downregulation: NAMPT (nicotinamide phosphoribosyltransferase) is the rate-limiting enzyme in the NAD+ salvage pathway — the primary route for recycling nicotinamide back into NAD+. NAMPT activity declines with age and is suppressed by inflammation and oxidative stress.
• CD38 upregulation: As described above, CD38 expression increases with the chronic low-grade inflammation of aging ("inflammaging"), dramatically accelerating NAD+ consumption.
• Increased PARP activity: Accumulated DNA damage with aging keeps PARP enzymes chronically activated, creating a sustained drain on NAD+ pools.
• Reduced tryptophan conversion: The de novo NAD+ synthesis pathway from dietary tryptophan becomes less efficient with age and is disrupted by gut dysbiosis.

Clinical Correlates of NAD+ Decline

Population studies and clinical observations have linked low NAD+ status with a cluster of age-associated conditions: chronic fatigue, cognitive decline, reduced exercise tolerance, metabolic syndrome, and impaired immune function. Biomarkers that tend to track with NAD+ status include mitochondrial function tests (VO2 max, lactate threshold), inflammatory markers (IL-6, CRP), and self-reported energy and cognitive function scores. None of these are specific to NAD+ — but in aggregate, they paint a picture of accelerated cellular aging that NAD+ repletion may help reverse.

Intracellular vs. Blood NAD+ Testing: What to Measure and Where to Go

This is where most people make a critical error. Standard metabolic panels and even many specialty labs measure NAD+ in serum or plasma — but serum NAD+ reflects what is circulating between cells, not what is actually inside them. Intracellular NAD+ is the biologically relevant number, and it can differ dramatically from serum values.

Why Intracellular Measurement Matters

Supplementation with NMN or NR raises blood NAD+ levels measurably — but the more important question is whether NAD+ is actually being taken up and utilized inside cells. Some individuals appear to be "blood raisers" — their serum NAD+ responds well to supplementation, but intracellular uptake is limited. Others show robust intracellular responses. Only a true intracellular test can distinguish these scenarios and guide dosing decisions.

The gold standard method measures NAD+ in peripheral blood mononuclear cells (PBMCs) — the white blood cells that are most accessible from a standard blood draw and that have well-characterized NAD+ metabolism. Whole blood measurements are also used and are slightly easier to process but may be influenced by red blood cell NAD+ content, which has different kinetics.

Testing Providers

• Jinfiniti Precision Medicine — Intracellular NAD+ Test: The most widely used direct-to-consumer intracellular NAD+ test. Uses a PBMC-based assay to measure NAD+ directly inside immune cells. Cost approximately $150–$300 per test. Provides an absolute value in nanomoles per milligram of protein, with reference ranges stratified by age group. This is the test most clinical longevity practitioners rely on for supplementation titration.
• iollo Metabolomics: A comprehensive metabolomics panel that includes NAD+ and related metabolites (NADH, NAM, NMN, NR) as part of a broader 500+ metabolite blood analysis. Useful for understanding the full NAD+ metabolism picture, including which bottlenecks may be limiting your production or increasing consumption. Typically costs more than a standalone NAD+ test but provides richer context.
• Vibrant America — Mitochondrial Metabolites Panel: Includes NAD+ along with other mitochondrial function markers. Often ordered through integrative medicine practitioners. Useful when combining NAD+ assessment with broader mitochondrial health evaluation.

What Normal Looks Like at Different Ages

Using Jinfiniti's PBMC assay as a reference framework:

• Ages 20–30: Optimal range typically 25–40 µM (relative units vary by assay normalization). High energy, robust mitochondrial function expected.
• Ages 40–50: Common range 15–25 µM. Many individuals begin noticing fatigue, reduced recovery, and early cognitive changes in this range.
• Ages 60+: Levels commonly fall to 10–18 µM without intervention. Values below 15 µM consistently correlate with fatigue, poor sleep quality, and reduced exercise tolerance in clinical observation.

These ranges should be interpreted as relative guides, not absolute thresholds. Individual variation is significant, and optimal levels depend on activity demands, health status, and genetic factors affecting NAD+ metabolism.

NMN vs NR vs Niacin vs Tryptophan: Which NAD+ Precursor Is Right for You?

The NAD+ precursor market is crowded and sometimes confusing. Each precursor enters the NAD+ biosynthesis pathway at a different point, has different pharmacokinetics, and may have different tissue targeting. Here is what the evidence shows.

NMN (Nicotinamide Mononucleotide)

NMN is one step closer to NAD+ than NR in the salvage pathway. Human trials have confirmed that oral NMN raises blood NAD+ levels, and Jinfiniti's clinical data shows that 500 mg/day raises intracellular NAD+ by 40–60% within 30–60 days in most adults. NMN has a transporter (Slc12a8) in the small intestine that may allow some direct cellular uptake, though it also converts to NR in circulation. Higher doses (1,000–2,000 mg/day) have been used in some clinical trials without apparent safety concerns. Sublingual and liposomal formulations are marketed for improved bioavailability, though direct comparative data is limited.

NR (Nicotinamide Riboside)

NR was the first NAD+ precursor to achieve significant clinical trial data in humans. Multiple randomized controlled trials have confirmed that NR at 250–1,000 mg/day raises blood NAD+ by 40–90%. NR converts to NMN intracellularly before final conversion to NAD+. Some research suggests NR may preferentially raise NAD+ in liver and muscle tissue. NR is also well-tolerated with no significant adverse effects reported in clinical trials up to 2,000 mg/day.

Niacin (Nicotinic Acid)

Niacin is the oldest and cheapest NAD+ precursor, and in some ways the most potent — it not only raises NAD+ but also strongly suppresses CD38 expression through its GPR109A receptor, creating a dual mechanism that oral NMN and NR do not share. The limitation is the well-known "niacin flush" (prostaglandin-mediated skin flushing) that occurs at doses above 100 mg and can be quite uncomfortable. Slow-release niacin reduces flushing but may increase liver enzyme elevation risk. Very low-dose niacin (25–50 mg) combined with NMN or NR is a strategy some clinicians use to get the CD38-suppressing benefit without the flush.

Tryptophan → Kynurenine → NAD+ (De Novo Pathway)

The body can synthesize NAD+ from dietary tryptophan through the kynurenine pathway. This is energetically expensive (approximately 60 mg of tryptophan is required to produce 1 mg of NAD+) and is heavily regulated by the enzyme IDO1, which is upregulated by inflammation and aging. This pathway is generally not a viable supplementation strategy but is relevant for understanding total NAD+ biology — gut dysbiosis and chronic inflammation can throttle de novo synthesis significantly, making the salvage pathway precursors even more important.

CD38 Inhibitor Synergy: Apigenin and Quercetin

Taking NAD+ precursors without addressing CD38-driven consumption is like increasing water pressure in a pipe that has a large hole in it. Two natural flavonoids have demonstrated meaningful CD38 inhibition:

• Apigenin: A flavone found in parsley, chamomile, and celery. Animal studies have shown that apigenin supplementation significantly reduces CD38 activity and raises NAD+ levels. Typical doses used in research range from 50–200 mg/day. Apigenin also shows weak senolytic activity and may have complementary mechanisms to NAD+ repletion.
• Quercetin: A flavonol found widely in onions, capers, and berries. Quercetin inhibits CD38 and also has SIRT1-activating effects. Like apigenin, it is poorly bioavailable in standard forms — liposomal or phytosome formulations significantly improve absorption. Quercetin is also the most studied senolytic compound (in the dasatinib + quercetin combination used in clinical senolysis trials).

Combining NMN or NR with a CD38 inhibitor stack (apigenin + quercetin) represents the most mechanistically complete approach to raising and sustaining intracellular NAD+ levels currently available.

NAD+ Precursor Evidence Table

The NAD+ Testing Protocol: Baseline, Optimization, and Annual Monitoring

Testing without a protocol is data without action. The goal is not just to get a number — it is to establish a feedback loop between your supplementation, lifestyle, and measurable intracellular NAD+ response. Here is how to structure that loop.

Factors That Deplete NAD+

Before designing your protocol, understand what is working against you. The most significant NAD+ depleting factors include:

• Alcohol consumption: Alcohol metabolism converts NAD+ to NADH at a high rate, and chronic alcohol use significantly depresses cellular NAD+ pools. Even moderate regular alcohol use impairs NAD+ status.
• Chronic inflammation: Systemic inflammation upregulates CD38, increases PARP activation, and suppresses NAMPT. Inflammatory conditions — obesity, autoimmune disease, metabolic syndrome — all accelerate NAD+ depletion.
• DNA damage: High cumulative UV exposure, smoking, environmental toxins, and oxidative stress maintain chronically elevated PARP activity, draining NAD+ reserves continuously.
• Aging itself: As described throughout this guide, the enzymatic and expression changes of aging compound to reduce both synthesis and increase consumption simultaneously.
• Shift work and circadian disruption: NAMPT, the key NAD+ biosynthesis enzyme, has a strong circadian expression pattern. Chronic circadian disruption (shift work, frequent transmeridian travel, irregular sleep) suppresses NAMPT and impairs NAD+ production cycles.

Lifestyle Interventions That Raise NAD+

Supplements are not the only lever. Several lifestyle interventions have strong mechanistic and observational support for raising NAD+ levels:

• Exercise: Resistance and endurance exercise both upregulate NAMPT expression in skeletal muscle, directly increasing NAD+ biosynthetic capacity. This may partly explain why exercise mimics many of the proposed benefits of NAD+ supplementation. Even a single bout of high-intensity exercise raises muscle NAMPT activity acutely.
• Caloric restriction and intermittent fasting: CR and fasting increase the NAD+/NADH ratio by reducing NADH production from food metabolism, effectively raising the proportion of NAD+ available for sirtuin and other enzymatic functions.
• Sauna: Heat stress upregulates heat shock proteins and activates SIRT1, and some evidence suggests it may also modestly raise NAMPT activity. The hormetic stress of regular sauna use (3–5x/week, 15–20 minutes at 80–90°C) appears to compound with other NAD+ interventions.

Interpreting Your Test Results

When you receive your Jinfiniti or iollo results, look for these key signals:

• A baseline value in the lower quartile for your age group is a strong indication for supplementation intervention.
• If your 60-day follow-up shows less than 20–25% increase despite consistent NMN supplementation, consider: (a) adding a CD38 inhibitor, (b) increasing dose, (c) evaluating inflammatory markers that may be driving CD38 upregulation, or (d) checking MTHFR and other metabolic SNPs that may affect precursor conversion.
• If your levels are above the optimal range for your age, this is generally not a concern — NAD+ does not appear to have a known toxicity at physiologic or supraphysiologic levels from oral supplementation, though very high levels have not been studied long-term.
• Annual retesting is sufficient for maintenance once you have found your optimal protocol. Retest within 60 days of any significant protocol change (new supplement, major dietary shift, illness, or new medication).